Paroxetine maleate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 563324

CAS#: 64006-44-6 (maleate)

Description: Paroxetine is a potent and one of the most specific selective serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitors (SSRIs).It acts by binding to ST (serotonin transporter/SERT) with high affinity. Paroxetine binds to the pre-synaptic serotonin transporter complex resulting in negative allosteric modulation of the complex thereby blocking reuptake of serotonin by the pre-synaptic transporter. Paroxetine HCl has also displayed a high affinity for muscarinic acetylcholine receptors.


Chemical Structure

img
Paroxetine maleate
CAS# 64006-44-6 (maleate)

Theoretical Analysis

MedKoo Cat#: 563324
Name: Paroxetine maleate
CAS#: 64006-44-6 (maleate)
Chemical Formula: C23H24FNO7
Exact Mass: 445.15
Molecular Weight: 445.440
Elemental Analysis: C, 62.02; H, 5.43; F, 4.27; N, 3.14; O, 25.14

Price and Availability

Size Price Availability Quantity
10mg USD 550 2 Weeks
50mg USD 1450 2 Weeks
Bulk inquiry

Related CAS #: 61869-08-7 (free base)   64006-44-6 (maleate)   78246-49-8 (HCl)   72471-80-8 (acetate)   217797-14-3 (mesylate)   110429-35-1 (HCl hydrate)    

Synonym: Paroxetine maleate; Paroxetine maleate salt;

IUPAC/Chemical Name: (3S-trans)-3-[(1,3-Benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine maleate salt

InChi Key: AEIUZSKXSWGSRU-QXGDPHCHSA-N

InChi Code: InChI=1S/C19H20FNO3.C4H4O4/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18;5-3(6)1-2-4(7)8/h1-6,9,14,17,21H,7-8,10-12H2;1-2H,(H,5,6)(H,7,8)/b;2-1-/t14-,17-;/m0./s1

SMILES Code: FC1=CC=C([C@H]2[C@H](COC3=CC=C(OCO4)C4=C3)CNCC2)C=C1.O=C(O)/C=C\C(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 445.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Wang Y, Zhang A, Dilinuer A, Hao L, Hu Z, Jia W. Meta-analysis of acupuncture combined with paroxetine in the treatment of depression. Am J Transl Res. 2022 Dec 15;14(12):8429-8436. PMID: 36628233; PMCID: PMC9827301.


2: Zeng M, Gong A, Wu Z. Paroxetine combined with traditional chinese medicine prescriptions in the treatment of postpartum depression: A systematic review of randomized controlled trials. Front Neuroendocrinol. 2022 Oct;67:101019. doi: 10.1016/j.yfrne.2022.101019. Epub 2022 Aug 1. PMID: 35926637.


3: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Paroxetine. 2022 May 15. PMID: 30000249.


4: David PS, Smith TL, Nordhues HC, Kling JM. A Clinical Review on Paroxetine and Emerging Therapies for the Treatment of Vasomotor Symptoms. Int J Womens Health. 2022 Mar 10;14:353-361. doi: 10.2147/IJWH.S282396. PMID: 35300283; PMCID: PMC8921794.


5: Mother To Baby | Fact Sheets [Internet]. Brentwood (TN): Organization of Teratology Information Specialists (OTIS); 1994–. Paroxetine. 2021 Mar 1. PMID: 35952169.


6: Kowalska M, Nowaczyk J, Fijałkowski Ł, Nowaczyk A. Paroxetine-Overview of the Molecular Mechanisms of Action. Int J Mol Sci. 2021 Feb 7;22(4):1662. doi: 10.3390/ijms22041662. PMID: 33562229; PMCID: PMC7914979.


7: Santos J, Proença MF, Rodrigues AJ, Patrício P, Domingues HS. Recent Advances in the Synthesis of the Antidepressant Paroxetine. Curr Med Chem. 2021;28(15):2960-2973. doi: 10.2174/0929867327666201026144848. PMID: 33106133.


8: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Paroxetine. 2020 Apr 8. PMID: 31643629.


9: Li L, Han Z, Li L, Han L, Yan B. Effectiveness of Paroxetine for Poststroke Depression: A Meta-Analysis. J Stroke Cerebrovasc Dis. 2020 May;29(5):104664. doi: 10.1016/j.jstrokecerebrovasdis.2020.104664. Epub 2020 Feb 21. PMID: 32093988.


10: Feduccia AA, Jerome L, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R. Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline. Front Psychiatry. 2019 Sep 12;10:650. doi: 10.3389/fpsyt.2019.00650. PMID: 31572236; PMCID: PMC6751381.


11: Nevels RM, Gontkovsky ST, Williams BE. Paroxetine-The Antidepressant from Hell? Probably Not, But Caution Required. Psychopharmacol Bull. 2016 Mar 1;46(1):77-104. PMID: 27738376; PMCID: PMC5044489.


12: Wei D, Chen Y, Wu C, Wu Q, Yao L, Wang Q, Wang XQ, Yang KH. Effect and safety of paroxetine for vasomotor symptoms: systematic review and meta- analysis. BJOG. 2016 Oct;123(11):1735-43. doi: 10.1111/1471-0528.13951. Epub 2016 Apr 7. PMID: 27062457.


13: Bérard A, Iessa N, Chaabane S, Muanda FT, Boukhris T, Zhao JP. The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016 Apr;81(4):589-604. doi: 10.1111/bcp.12849. Epub 2016 Jan 26. PMID: 26613360; PMCID: PMC4799922.


14: Bhat IA, Shannon KD, Ara A, Coe I. Ninety-six hours ordeal of priapism induced by paroxetine--A case report and literature review. Int J Psychiatry Med. 2015;50(3):326-34. doi: 10.1177/0091217415610312. Epub 2015 Oct 5. PMID: 26443710.


15: Carroll DG, Lisenby KM, Carter TL. Critical appraisal of paroxetine for the treatment of vasomotor symptoms. Int J Womens Health. 2015 Jun 18;7:615-24. doi: 10.2147/IJWH.S50804. PMID: 26124682; PMCID: PMC4476484.


16: Slaton RM, Champion MN, Palmore KB. A review of paroxetine for the treatment of vasomotor symptoms. J Pharm Pract. 2015 Jun;28(3):266-74. doi: 10.1177/0897190014544785. Epub 2014 Aug 8. PMID: 25107421.


17: Carris N, Kutner S, Reilly-Rogers S. New pharmacological therapies for vasomotor symptom management: focus on bazedoxifene/conjugated estrogens and paroxetine mesylate. Ann Pharmacother. 2014 Oct;48(10):1343-9. doi: 10.1177/1060028014543099. Epub 2014 Jul 15. PMID: 25028744.


18: Purgato M, Papola D, Gastaldon C, Trespidi C, Magni LR, Rizzo C, Furukawa TA, Watanabe N, Cipriani A, Barbui C. Paroxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2014 Apr 3;2014(4):CD006531. doi: 10.1002/14651858.CD006531.pub2. PMID: 24696195; PMCID: PMC10091826.


19: Weber L, Thacker HL. Paroxetine: a first for selective serotonin reuptake inhibitors - a new use: approved for vasomotor symptoms in postmenopausal women. Womens Health (Lond). 2014 Mar;10(2):147-54. doi: 10.2217/whe.14.3. PMID: 24601805.


20: Sanchez C, Reines EH, Montgomery SA. A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike? Int Clin Psychopharmacol. 2014 Jul;29(4):185-96. doi: 10.1097/YIC.0000000000000023. PMID: 24424469; PMCID: PMC4047306.